Thioredoxin Signaling Pathways in Cancer
Antioxidants & Redox Signaling · 2023-02 · 38 (4-6) · 403-424
DOI: 10.1089/ars.2022.0074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 14.02.2023. Verfasst von Junmin Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Applied Organic Chemistry, School of Pharmacy, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Ch…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 281 Literaturangaben.
Abstract (Originalsprache)
Significance: Thioredoxin (Trx) is a powerful antioxidant that reduces protein disulfides to maintain redox stability in cells and is involved in regulating multiple redox-dependent signaling pathways. Recent Advance: The current accumulation of findings suggests that Trx participates in signaling pathways that interact with various proteins to manipulate their dynamic regulation of structure and function. These network pathways are critical for cancer pathogenesis and therapy. Promising clinical advances have been presented by most anticancer agents targeting such signaling pathways. Critical Issues: We herein link the signaling pathways regulated by the Trx system to potential cancer therapeutic opportunities, focusing on the coordination and strengths of the Trx signaling pathways in apoptosis, ferroptosis, immunomodulation, and drug resistance. We also provide a mechanistic network for the exploitation of therapeutic small molecules targeting the Trx signaling pathways. Future Directions: As research data accumulate, future complex networks of Trx-related signaling pathways will gain in detail. In-depth exploration and establishment of these signaling pathways, including Trx upstream and downstream regulatory proteins, will be critical to advancing novel cancer therapeutics. Antioxid. Redox Signal . 38, 403–424.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Applied Organic Chemistry, School of Pharmacy, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
- Regor Therapeutics, Inc., Shanghai, China.
- School of Chemistry and Chemical Engineering, Nanjing University of Science & Technology, Nanjing, China.
ORCID-Profile: Junmin Zhang
Zitieren
APA
Zhang, J., Li, X., Zhao, Z., Cai, W., & Fang, J. (2023). Thioredoxin Signaling Pathways in Cancer. Antioxidants & Redox Signaling, 38(4-6), 403-424. https://doi.org/10.1089/ars.2022.0074
Vancouver
Zhang J, Li X, Zhao Z, Cai W, Fang J. Thioredoxin Signaling Pathways in Cancer. Antioxidants & Redox Signaling. 2023;38(4-6):403-424. doi:10.1089/ars.2022.0074
BibTeX
@article{Zhang2023,
author = {Zhang, Junmin and Li, Xinming and Zhao, Zhengjia and Cai, Wenqing and Fang, Jianguo},
title = {Thioredoxin Signaling Pathways in Cancer},
journal = {Antioxidants & Redox Signaling},
year = {2023},
volume = {38},
number = {4-6},
pages = {403--424},
doi = {10.1089/ars.2022.0074}
}
EUVIMED